magnifying glass
logo for Koligo Therapeutics

Koligo Therapeutics

Manufacturing · Indiana, United States · <25 Employees

Get Full Access

Who is Koligo Therapeutics

Koligo Therapeutics, Inc. is a US regenerative medicine company. Koligo's first commercial product is KYSLECEL® (autologous pancreatic islets) for chronic and acute recurrent pancreatitis. Koligo's 3D-V technology platform incorporates the use of advanced 3D bioprinting techniques and vascular endothelial cells to support development of transformational cell and tissue products for serious diseases.Read More



2113 State St, New Albany, Indiana, 47150, United States
Phone Number

Phone Number:

(502) 265-4830


<$5 Million
Koligo Therapeutics's Social Media
SIC Code 28,283
NAICS Code 3254,32541
Popular Searches:

Koligo Therapeutics Inc

Koligo Therapeutics

Koligo Therapeutics , Inc.

Legato Therapeutics Inc

Koligo Therapeutics - Inc

Koligo Therapeutics's Org Chart

Matthew Lehman
Matthew Lehman

Chief Executive Officer

Stuart Williams
Stuart Williams

Chief Technology Officer

Paul Kosnik
Paul Kosnik

President, Clinical Development


Illustration of an envelope

Koligo Therapeutics's Tech Stack

GoDaddy DNS


Google Cloud DNS






Office 365


See more technologies

Koligo Therapeutics News & Media

Orgenesis Completes Acquisition of Koligo Therapeutics and Announces Additional Acquisition of Icellator® Technology from Tissue Genesis in Related Transaction

Icellator® commercially available for lipotransfer in first two countries with more approvals expected Icellator® commercially available for lipotransfer in first two countries with more approvals expected

Orgenesis Announces Agreement to Acquire Koligo Therapeutics, a Leader in Personalized Cell Therapies

Acquisition to support accelerated commercialization of Koligo’s KYSLECEL®, a personalized islet cell therapy available in the U.S. for chronic and recurrent acute pancreatitis

Koligo Therapeutics to Participate in Maxim Group and M-Vest COVID-19 Virtual Conference Series on May 27, 2020

NEW ALBANY, INDIANA, UNITED STATES, May 22, 2020 /⁨⁩/ -- Koligo Therapeutics, Inc. (Koligo), a privately-held regenerative medicine company, today announced that Matthew Lehman, Chief Executive Officer, will be participating in the Maxim …
Subscribe to "Koligo Therapeutics" News

Frequently Asked Questions regarding Koligo Therapeutics

Where are Koligo Therapeutics’s headquarters?

Koligo Therapeutics’s headquarters are in 2113 State St, New Albany, Indiana, 47150, United States

What is Koligo Therapeutics’s phone number?

Koligo Therapeutics’s phone number is (502) 265-4830

What is Koligo Therapeutics’s official website?

Koligo Therapeutics’s official website is

What is Koligo Therapeutics’s Revenue?

Koligo Therapeutics’s revenue is <$5 Million

What is Koligo Therapeutics’s SIC code?

Koligo Therapeutics’s SIC: 28,283

What is Koligo Therapeutics’s NAICS code?

Koligo Therapeutics’s NAICS: 3254,32541

How many employees are working in Koligo Therapeutics?

Koligo Therapeutics has <25 employees

What is Koligo Therapeutics’s industry?

Koligo Therapeutics is in the industry of: Manufacturing, Pharmaceuticals

What is Koligo Therapeutics's tech stack?

The technologies that are used by Koligo Therapeutics are: GoDaddy DNS, Google Cloud DNS, DigitalOcean, Office 365

Who is Koligo Therapeutics's CEO?

Koligo Therapeutics's CEO is Matthew Lehman

Who is Koligo Therapeutics's CTO?

Koligo Therapeutics's CTO is Stuart Williams

See more information about Koligo Therapeutics
4.4/5 on G2 Crowd